1460-34-0
1460-34-0
Chemical Structure
3-Methyl-2-oxovaleric acid
- CAS. Nr.: 1460-34-0
- Formula:C6H10O3
- Molecular Weight:130.14
IUPAC Name: 3-methyl-2-oxopentanoic acid
InChIKey: JVQYSWDUAOAHFM-UHFFFAOYSA-N
SMILES: CCC(C)C(C(O)=O)=O
Biological Activity: 3-Methyl-2-oxovaleric acid is a degradation product from Isoleucine. 3-Methyl-2-oxovaleric acid is a biomarker of mustard airway diseases (MADs) and uric acid stone[1][2].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
3-Methyl-2-oxovaleric acid | 98.37% | 3-Methyl-2-oxovaleric acid is a degradation product from Isoleucine. 3-Methyl-2-oxovaleric acid is a biomarker of mustard airway diseases (MADs) and uric acid stone. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
3-Methyl-2-oxovaleric acid (Standard) | 99.86% | 3-Methyl-2-oxovaleric acid (Standard) is the analytical standard of 3-Methyl-2-oxovaleric acid (HY-113063). This product is intended for research and analytical applications. 3-Methyl-2-oxovaleric acid is a degradation product from Isoleucine. 3-Methyl-2-oxovaleric acid is a biomarker of mustard airway diseases (MADs) and uric acid stone. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
3-Methyl-2-oxovaleric acid-d8 sodium | 99.74% | 3-Methyl-2-oxovaleric acid-d8 sodium is the deuterium labeled 3-Methyl-2-oxovaleric acid. 3-Methyl-2-oxovaleric acid is a degradation product from Isoleucine. 3-Methyl-2-oxovaleric acid is a biomarker of mustard airway diseases (MADs) and uric acid stone. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Ghoochani BFNM, et, al. Metabolomics diagnostic approach to mustard airway diseases: a preliminary study. Iran J Basic Med Sci. 2018 Jan;21(1):59-69. [Content Brief]
- [2]. Xu S, et al. Self-control study of multi-omics in identification of microenvironment characteristics in urine of uric acid stone. Sci Rep. 2024 Oct 24;14(1):25165. [Content Brief]
